北京慧宝源生物技术股份有限公司 Mediaroom - PR Newswire APAC

Search

北京慧宝源生物技术股份有限公司

Latest News

R&D Milestone: HebaBiz Biotech's application for phase III clinical trial in China for Clevudine (L-FMAU), an anti-hepatitis B virus drug candidate under development has been approved

BEIJING, Nov. 15, 2021 /PRNewswire/ -- HebaBiz Biotech is pleased to announce that inNovember 2021,...

2021-11-15 22:47 1980

HebaBiz Biotech's anti-cancer drug candidate under development Siroquine (JP001) has been approved for IND clinical trials in the United States

BEIJING, Aug. 20, 2021 /PRNewswire/ -- HebaBiz Biotech is pleased to announce, it has come to its k...

2021-08-20 19:45 3127